tiprankstipranks
Trending News
More News >
MacroGenics Inc (MGNX)
:MGNX
US Market

MacroGenics (MGNX) Stock Forecast & Price Target

Compare
667 Followers
See the Price Targets and Ratings of:

MGNX Analyst Ratings

Moderate Buy
7Ratings
Moderate Buy
2 Buy
5 Hold
0 Sell
Based on 7 analysts giving stock ratings to
MacroGenics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MGNX Stock 12 Month Forecast

Average Price Target

$4.20
▲(189.66%Upside)
Based on 7 Wall Street analysts offering 12 month price targets for MacroGenics in the last 3 months. The average price target is $4.20 with a high forecast of $8.00 and a low forecast of $2.00. The average price target represents a 189.66% change from the last price of $1.45.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","10":"$10","15":"$15","20":"$20"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5,10,15,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Oct<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.68,2.166153846153846,2.6523076923076925,3.1384615384615384,3.6246153846153844,4.110769230769231,4.596923076923077,5.083076923076923,5.569230769230769,6.055384615384615,6.541538461538462,7.027692307692307,7.513846153846154,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.68,1.873846153846154,2.0676923076923077,2.2615384615384615,2.4553846153846157,2.6492307692307695,2.8430769230769233,3.0369230769230775,3.230769230769231,3.424615384615385,3.618461538461539,3.8123076923076926,4.006153846153847,{"y":4.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.68,1.7046153846153846,1.7292307692307691,1.7538461538461538,1.7784615384615383,1.803076923076923,1.8276923076923077,1.8523076923076922,1.876923076923077,1.9015384615384616,1.926153846153846,1.9507692307692308,1.9753846153846153,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.18,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.27,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.06,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.02,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.55,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.43,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$8.00Average Price Target$4.20Lowest Price Target$2.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on MGNX
TipRanks AITipRanks
Not Ranked
TipRanks
$1.5
Hold
3.45%
Upside
Reiterated
06/06/25
MacroGenics' score is primarily influenced by its mixed financial performance with growth offset by profitability challenges. Technical analysis suggests bearish momentum, and valuation remains difficult due to negative earnings. Positive earnings call insights mitigate some risks, highlighting revenue growth and a solid cash position.
B.Riley Financial Analyst forecast on MGNX
Mayank MamtaniB.Riley Financial
B.Riley Financial
$5$3
Hold
106.90%
Upside
Reiterated
05/20/25
MacroGenics price target lowered to $3 from $5 at B. RileyMacroGenics price target lowered to $3 from $5 at B. Riley
Stifel Nicolaus Analyst forecast on MGNX
Stephen WilleyStifel Nicolaus
Stifel Nicolaus
$6$5
Hold
244.83%
Upside
Reiterated
05/14/25
MacroGenics price target lowered to $5 from $6 at StifelMacroGenics price target lowered to $5 from $6 at Stifel
Barclays Analyst forecast on MGNX
Peter LawsonBarclays
Barclays
$8$3
Buy
106.90%
Upside
Reiterated
05/14/25
MacroGenics (MGNX) Gets a Buy from Barclays
TD Cowen
Hold
Reiterated
05/13/25
TD Cowen Sticks to Its Hold Rating for MacroGenics (MGNX)
Leerink Partners Analyst forecast on MGNX
Jonathan ChangLeerink Partners
Leerink Partners
$8
Buy
451.72%
Upside
Reiterated
05/13/25
MacroGenics: Strategic Pipeline Shifts and Financial Stability Justify Buy Rating
H.C. Wainwright Analyst forecast on MGNX
Robert BurnsH.C. Wainwright
H.C. Wainwright
$2
Hold
37.93%
Upside
Reiterated
03/25/25
MacroGenics: Hold Rating Amidst Development Halts and Financial Challenges
Citizens JMP Analyst forecast on MGNX
Silvan TuerkcanCitizens JMP
Citizens JMP
Hold
Reiterated
03/21/25
MacroGenics Hold Rating: Uncertainty in Pipeline and Fair Valuation Amidst Anticipated 2025 Updates
Evercore ISI Analyst forecast on MGNX
Jonathan MillerEvercore ISI
Evercore ISI
Buy
Reiterated
09/16/24
Evercore ISI Sticks to Their Buy Rating for MacroGenics (MGNX)
Citi
$16$14
Buy
865.52%
Upside
Reiterated
08/15/24
MacroGenics price target lowered to $14 from $16 at CitiMacroGenics price target lowered to $14 from $16 at Citi
Guggenheim Analyst forecast on MGNX
Kelsey GoodwinGuggenheim
Guggenheim
Hold
Downgraded
07/30/24
MacroGenics (MGNX) was downgraded to a Hold Rating at Guggenheim
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on MGNX
TipRanks AITipRanks
Not Ranked
TipRanks
$1.5
Hold
3.45%
Upside
Reiterated
06/06/25
MacroGenics' score is primarily influenced by its mixed financial performance with growth offset by profitability challenges. Technical analysis suggests bearish momentum, and valuation remains difficult due to negative earnings. Positive earnings call insights mitigate some risks, highlighting revenue growth and a solid cash position.
B.Riley Financial Analyst forecast on MGNX
Mayank MamtaniB.Riley Financial
B.Riley Financial
$5$3
Hold
106.90%
Upside
Reiterated
05/20/25
MacroGenics price target lowered to $3 from $5 at B. RileyMacroGenics price target lowered to $3 from $5 at B. Riley
Stifel Nicolaus Analyst forecast on MGNX
Stephen WilleyStifel Nicolaus
Stifel Nicolaus
$6$5
Hold
244.83%
Upside
Reiterated
05/14/25
MacroGenics price target lowered to $5 from $6 at StifelMacroGenics price target lowered to $5 from $6 at Stifel
Barclays Analyst forecast on MGNX
Peter LawsonBarclays
Barclays
$8$3
Buy
106.90%
Upside
Reiterated
05/14/25
MacroGenics (MGNX) Gets a Buy from Barclays
TD Cowen
Hold
Reiterated
05/13/25
TD Cowen Sticks to Its Hold Rating for MacroGenics (MGNX)
Leerink Partners Analyst forecast on MGNX
Jonathan ChangLeerink Partners
Leerink Partners
$8
Buy
451.72%
Upside
Reiterated
05/13/25
MacroGenics: Strategic Pipeline Shifts and Financial Stability Justify Buy Rating
H.C. Wainwright Analyst forecast on MGNX
Robert BurnsH.C. Wainwright
H.C. Wainwright
$2
Hold
37.93%
Upside
Reiterated
03/25/25
MacroGenics: Hold Rating Amidst Development Halts and Financial Challenges
Citizens JMP Analyst forecast on MGNX
Silvan TuerkcanCitizens JMP
Citizens JMP
Hold
Reiterated
03/21/25
MacroGenics Hold Rating: Uncertainty in Pipeline and Fair Valuation Amidst Anticipated 2025 Updates
Evercore ISI Analyst forecast on MGNX
Jonathan MillerEvercore ISI
Evercore ISI
Buy
Reiterated
09/16/24
Evercore ISI Sticks to Their Buy Rating for MacroGenics (MGNX)
Citi
$16$14
Buy
865.52%
Upside
Reiterated
08/15/24
MacroGenics price target lowered to $14 from $16 at CitiMacroGenics price target lowered to $14 from $16 at Citi
Guggenheim Analyst forecast on MGNX
Kelsey GoodwinGuggenheim
Guggenheim
Hold
Downgraded
07/30/24
MacroGenics (MGNX) was downgraded to a Hold Rating at Guggenheim
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering MacroGenics

1 Month
xxx
Success Rate
10/30 ratings generated profit
33%
Average Return
-3.55%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of -3.55% per trade.
3 Months
xxx
Success Rate
8/22 ratings generated profit
36%
Average Return
-21.50%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 36.36% of your transactions generating a profit, with an average return of -21.50% per trade.
1 Year
Jonathan ChangLeerink Partners
Success Rate
8/30 ratings generated profit
27%
Average Return
-22.49%
reiterated a buy rating 25 days ago
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 26.67% of your transactions generating a profit, with an average return of -22.49% per trade.
2 Years
xxx
Success Rate
4/30 ratings generated profit
13%
Average Return
-49.65%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 13.33% of your transactions generating a profit, with an average return of -49.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MGNX Analyst Recommendation Trends

Rating
Sep 24
Oct 24
Nov 24
Mar 25
May 25
Strong Buy
7
5
3
5
6
Buy
3
2
2
0
0
Hold
14
9
12
13
17
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
16
17
18
23
In the current month, MGNX has received 6 Buy Ratings, 17 Hold Ratings, and 0 Sell Ratings. MGNX average Analyst price target in the past 3 months is 4.20.
Each month's total comprises the sum of three months' worth of ratings.

MGNX Financial Forecast

MGNX Earnings Forecast

Next quarter’s earnings estimate for MGNX is -$0.61 with a range of -$0.75 to -$0.33. The previous quarter’s EPS was -$0.65. MGNX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year MGNX has Outperformed its overall industry.
Next quarter’s earnings estimate for MGNX is -$0.61 with a range of -$0.75 to -$0.33. The previous quarter’s EPS was -$0.65. MGNX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year MGNX has Outperformed its overall industry.

MGNX Sales Forecast

Next quarter’s sales forecast for MGNX is $16.74M with a range of $7.50M to $36.00M. The previous quarter’s sales results were $13.19M. MGNX beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year MGNX has Outperformed its overall industry.
Next quarter’s sales forecast for MGNX is $16.74M with a range of $7.50M to $36.00M. The previous quarter’s sales results were $13.19M. MGNX beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year MGNX has Outperformed its overall industry.

MGNX Stock Forecast FAQ

What is MGNX’s average 12-month price target, according to analysts?
Based on analyst ratings, MacroGenics Inc’s 12-month average price target is 4.20.
    What is MGNX’s upside potential, based on the analysts’ average price target?
    MacroGenics Inc has 189.66% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MGNX a Buy, Sell or Hold?
          MacroGenics Inc has a consensus rating of Moderate Buy which is based on 2 buy ratings, 5 hold ratings and 0 sell ratings.
            What is MacroGenics Inc’s price target?
            The average price target for MacroGenics Inc is 4.20. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $8.00 ,the lowest forecast is $2.00. The average price target represents 189.66% Increase from the current price of $1.45.
              What do analysts say about MacroGenics Inc?
              MacroGenics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of MGNX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis